Vergelijking
LL-37 vs. Pasireotid
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
597562-32-8
396091-73-9
Molecuulmassa
4493.33 g/mol
1047.21 g/mol
Halfwaardetijd
geen gegevens
geen gegevens
Sequentie
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESgeen gegevens
Werkingsmechanisme
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Pasireotid
Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.
Bewijsbasis
Hoogste bewijs
Humane studie
Humane RCT
Studies
4
1
waarvan bij mensen
1
1
Geregistreerde effecten
4
2
Openstaande tegenstrijdigheden
1
0
Gedocumenteerde bijwerkingen
0
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between LL-37 and Pasireotid?
- LL-37 is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Pasireotid?
- The highest available evidence level is "Humane studie" for LL-37 and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Pasireotid in Germany and the United States?
- Duitsland: LL-37 — Alleen onderzoek, Pasireotid — Op recept. Verenigde Staten: LL-37 — Alleen onderzoek, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.